CSL Behring joins FoCUS
“CSL Behring strengthens our consortium’s perspectives on how to achieve patient impact with cutting-edge therapies,” said Gigi Hirsch, MD, executive director of NEWDIGS. “The science is necessary but not sufficient—in FoCUS, they can help us address challenges in the in the complex healthcare system that undermine the value that medical discoveries can deliver.”
Paying for Cures: Self-Insured Employers
Understand the challenges around new cell and gene therapies, and learn how to make them both accessible and sustainable. Register now
IN THE COMMUNITY
On April 12 Mark Trusheim led a workshop for ISPOR, entitled “Adaptive Reimbursement: Innovating for Patient Access and Better Outcomes for All”, including Angela Banks Vice President, External Affairs, UnitedHealth Group; Ron Potts, MD; Medical Director Quality Improvement Kaiser Permanente, Chief Medical Officer, INTERLINK; and David Strutton, PhD, VP, Global Pharmaceuticals & Policy Research, Center for Observational and Real-World Evidence, Merck & Co. Mark recaps the panel in this AJMC update.
NEWDIGS research was cited in “The use of innovative payment mechanisms for gene therapies in Europe and the USA” by Jesper Jørgensen and Panos Kefalas in Regenerative Medicine.
SAVE THE DATES
FoCUS 2021 Design Labs
October 12–14 (TBC). By invitation only.